These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 25282584

  • 1. Time course of contrast enhancement by micro-CT with dedicated contrast agents in normal mice and mice with hepatocellular carcinoma: comparison of one iodinated and two nanoparticle-based agents.
    Rothe JH, Rudolph I, Rohwer N, Kupitz D, Gregor-Mamoudou B, Derlin T, Furth C, Amthauer H, Brenner W, Buchert R, Cramer T, Apostolova I.
    Acad Radiol; 2015 Feb; 22(2):169-78. PubMed ID: 25282584
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Fenestra LC, ExiTron nano 6000, and ExiTron nano 12000 for micro-CT imaging of liver and spleen in mice.
    Boll H, Figueiredo G, Fiebig T, Nittka S, Doyon F, Kerl HU, Nölte I, Förster A, Kramer M, Brockmann MA.
    Acad Radiol; 2013 Sep; 20(9):1137-43. PubMed ID: 23931428
    [Abstract] [Full Text] [Related]

  • 3. A comparative analysis of water-soluble and blood-pool contrast agents for in vivo vascular imaging with micro-CT.
    Nebuloni L, Kuhn GA, Müller R.
    Acad Radiol; 2013 Oct; 20(10):1247-55. PubMed ID: 24029056
    [Abstract] [Full Text] [Related]

  • 4. Micro-CT based experimental liver imaging using a nanoparticulate contrast agent: a longitudinal study in mice.
    Boll H, Nittka S, Doyon F, Neumaier M, Marx A, Kramer M, Groden C, Brockmann MA.
    PLoS One; 2011 Oct; 6(9):e25692. PubMed ID: 21984939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of small animal CT contrast agents.
    Mannheim JG, Schlichthaerle T, Kuebler L, Quintanilla-Martinez L, Kohlhofer U, Kneilling M, Pichler BJ.
    Contrast Media Mol Imaging; 2016 Jul; 11(4):272-84. PubMed ID: 26991457
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contrast-enhanced micro-computed tomography using ExiTron nano6000 for assessment of liver injury.
    Hua XW, Lu TF, Li DW, Wang WG, Li J, Liu ZZ, Lin WW, Zhang JJ, Xia Q.
    World J Gastroenterol; 2015 Jul 14; 21(26):8043-51. PubMed ID: 26185375
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma.
    Maruyama H, Takahashi M, Ishibashi H, Okabe S, Yoshikawa M, Yokosuka O.
    Eur J Radiol; 2010 Jul 14; 75(1):e102-6. PubMed ID: 19783392
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recommended iodine dose for multiphasic contrast-enhanced mutidetector-row computed tomography imaging of liver for assessing hypervascular hepatocellular carcinoma: multicenter prospective study in 77 general hospitals in Japan.
    Ichikawa T, Okada M, Kondo H, Sou H, Murakami T, Kanematsu M, Yoshikawa S, Shiosakai K, Hayakawa A, Awai K, Yoshimitsu K, Yamashita Y.
    Acad Radiol; 2013 Sep 14; 20(9):1130-6. PubMed ID: 23931427
    [Abstract] [Full Text] [Related]

  • 14. Can low-dose CT with iterative reconstruction reduce both the radiation dose and the amount of iodine contrast medium in a dynamic CT study of the liver?
    Takahashi H, Okada M, Hyodo T, Hidaka S, Kagawa Y, Matsuki M, Tsurusaki M, Murakami T.
    Eur J Radiol; 2014 Apr 14; 83(4):684-91. PubMed ID: 24418284
    [Abstract] [Full Text] [Related]

  • 15. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK.
    Eur J Radiol; 2013 Feb 14; 82(2):327-34. PubMed ID: 23246016
    [Abstract] [Full Text] [Related]

  • 16. An imaging target TGF-β1 for hepatocellular carcinoma in mice.
    Zhang Y, Li B, Li X, Tan H, Cheng D, Shi H.
    Hell J Nucl Med; 2017 Feb 14; 20(1):76-78. PubMed ID: 28315912
    [Abstract] [Full Text] [Related]

  • 17. In Vivo Detection and Measurement of Aortic Aneurysm and Dissection in Mouse Models Using Microcomputed Tomography with Contrast Agent.
    Zhu G, Sun H, Wang J, Zhao Z, Bao J, Feng R, Zhou J, Jing Z.
    Contrast Media Mol Imaging; 2019 Feb 14; 2019():5940301. PubMed ID: 30956627
    [Abstract] [Full Text] [Related]

  • 18. Dynamic contrast-enhanced ultrasound (DCE-US) for easy and rapid evaluation of hepatocellular carcinoma compared to dynamic contrast-enhanced computed tomography (DCE-CT)--a pilot study.
    Egger C, Goertz RS, Strobel D, Lell M, Neurath MF, Knieling F, Scharf M.
    Ultraschall Med; 2012 Dec 14; 33(6):587-92. PubMed ID: 23154871
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of hypervascular hepatocellular carcinoma in cirrhotic liver by means of helical CT: comparison of different contrast medium concentrations within the same patient.
    Sultana S, Morishita S, Awai K, Kawanaka K, Ohyama Y, Nakayama Y, Imuta M, Arakawa A, Yamashita Y.
    Radiat Med; 2003 Dec 14; 21(6):239-45. PubMed ID: 14743896
    [Abstract] [Full Text] [Related]

  • 20. Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC.
    Willekens I, Lahoutte T, Buls N, Vanhove C, Deklerck R, Bossuyt A, de Mey J.
    Mol Imaging Biol; 2009 Dec 14; 11(2):128-35. PubMed ID: 19067081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.